Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 103 Carcinoma, Renal Cell 70 Neoplasm Metastasis 48 Neoplasms 37 Neuroendocrine Tumors 33 Kidney Neoplasms 27 Recurrence 19 Tuberous Sclerosis 18 Carcinoma, Non-Small-Cell Lung 17 Prostatic Neoplasms 16 Triple Negative Breast Neoplasms 15 Lymphoma 15 Lymphoma, Mantle-Cell 14 Lymphoma, Large B-Cell, Diffuse 14 Head and Neck Neoplasms 14 Glioblastoma 14 Colorectal Neoplasms 13 Carcinoma, Hepatocellular 13 Stomach Neoplasms 12 Lung Neoplasms 12 Leukemia, Lymphocytic, Chronic, B-Cell 12 Hodgkin Disease 12 Brain Neoplasms 12 Sarcoma 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 11 Pancreatic Neoplasms 11 Glioma 11 Waldenstrom Macroglobulinemia 10 Lymphoma, Follicular 10 Carcinoma, Neuroendocrine 10

Interventions

Gemcitabine 4 Cisplatin 4 pembrolizumab 3 Carboplatin 3 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 niraparib 1 enfortumab vedotin 1 cabozantinib 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Radiotherapy 1 Radiation Dose Hypofractionation 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Everolimus 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Urothelial Cancer × Everolimus × Clear all

NCT01801137 2016-06-21

AFINIVEST

Hopital Foch

Phase 2 Completed

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡